CLX Investment

CLX Investment Company, Inc. was a publicly traded healthcare company primarily focused on the acquisition, licensing, and distribution of innovative medical diagnostic technologies. The company's primary asset was a 51% equity interest in Zonda, Inc., a developer of rapid point-of-care diagnostic tests for infectious diseases. Its lead program was a rapid diagnostic test for chlamydia intended for both medical and non-medical markets. In 2008, the company announced a name change to CLX Medical, Inc. to better reflect its focus on the medical supply and rapid diagnostic segments. The company has since become inactive or undergone further corporate restructuring.